Abstract | BACKGROUND: METHODS: RESULTS: CONCLUSIONS: Chemohormonal therapy with estramustine phosphate plus LHRH agonist showed longer clinical progression-free survival than the hormonal therapy with flutamide plus LHRH agonist (P = 0.03), although there was no significant difference in the overall survival. A larger-scaled trial with more statistical power is required to clarify that the former regimen is more beneficial than the latter for newly diagnosed patients with advanced prostate cancer.
|
Authors | Masanori Noguchi, Shinshi Noda, Masaki Yoshida, Shoichi Ueda, Taizo Shiraishi, Kyogo Itoh, Kurume-Kumamoto Estracyt Study Group |
Journal | International journal of urology : official journal of the Japanese Urological Association
(Int J Urol)
Vol. 11
Issue 2
Pg. 103-9
(Feb 2004)
ISSN: 0919-8172 [Print] Australia |
PMID | 14706014
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Androgen Antagonists
- Antineoplastic Agents, Hormonal
- Gonadotropin-Releasing Hormone
- Estramustine
- Flutamide
|
Topics |
- Aged
- Aged, 80 and over
- Androgen Antagonists
(administration & dosage)
- Antineoplastic Agents, Hormonal
(administration & dosage)
- Disease-Free Survival
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Drug Therapy, Combination
- Estramustine
(administration & dosage)
- Flutamide
(administration & dosage)
- Gonadotropin-Releasing Hormone
(antagonists & inhibitors)
- Humans
- Male
- Middle Aged
- Neoplasm Invasiveness
(pathology)
- Neoplasm Staging
- Probability
- Prognosis
- Prostatic Neoplasms
(drug therapy, mortality, pathology)
- Survival Analysis
- Treatment Outcome
|